FIELD: pharmacology.
SUBSTANCE: pharmaceutical combination for patients with type 2 diabetes includes desPro36Exendin-4(1-39)-Lys6-NH2 and/or a pharmaceutically acceptable salt thereof, metformin and/or a pharmaceutically acceptable salt thereof and sulfonylurea. At that, the subject to be treated has postprandial plasma glucose concentration of at least 14 mmol/l 2 hours after ingestion. The group of inventions also relates to a method for plasma glucagon levels reduction in patients with type 2 diabetes comprising administration of the said combination.
EFFECT: reduced glucagon level in plasma.
22 cl, 11 dwg, 29 tbl, 2 ex
